lancet-header

Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.

Dabigatran Treatment of Acute Non-Cardioembolic Ischaemic Stroke: A Randomised Controlled Trial

95 Pages Posted: 28 Jan 2019

See all articles by Kenneth Butcher

Kenneth Butcher

University of Alberta - Division of Neurology

Kelvin Ng

McMaster University

Patrick Sheridan

David Braley Cardiac, Vascular and Stroke Research Institute (DBCVSRI) - Population Health Research Institute

Thalia S Field

McMaster University

Shelagh B Coutts

University of Calgary

Muzzafar Siddiqui

McMaster University

Laura C Gioia

University of Montreal

Brian Buck

University of Alberta

Michael D Hill

University of Calgary

Jodi Miller

McMaster University

Ana Klahr

University of Alberta

Leka Sivakumar

University of Alberta

Oscar R Benavente

University of British Columbia (UBC)

Robert G Hart

McMaster University

Mike Sharma

University of Alberta

More...

Abstract

Background: Transient ischaemic attack (TIA) and minor ischaemic stroke patients are at high risk for recurrent events. Anticoagulants are associated with reduced recurrent ischemic stroke rates, but also increased risk of haemorrhagic transformation (HT). Dabigatran, a novel oral anticoagulant associated with reduced risk of intracranial bleeding compared with warfarin in atrial fibrillation patients, has not been assessed in acute brain ischemia. We hypothesised that HT rates are not increased by dabigatran relative to aspirin after acute ischaemic stroke/TIA.

Methods: DAbigatran Treatment of Acute Stroke II (DATAS II) was a prospective, randomised open label, blinded endpoint trial of dabigatran versus aspirin in acute stroke/TIA (clinicatrials.gov NCT02295826). Non-cardio-embolic stroke/TIA patients (NIHSS score ≤9, infarct volume < 25 ml) who did not receive thrombolytic therapy or thrombectomy were randomised 1:1 to dabigatran 150 mg BID (110 mg BID in patients ≥80 or if CrCl <50 ml/min) or aspirin (81 mg OD). Magnetic resonance imaging was performed prior to randomisation and was repeated at day 30, with clinical assessments at 30 and 90 days. Imaging endpoints were ascertained centrally by readers blinded to treatment. The primary endpoint was symptomatic HT within 37 days of randomisation. Secondary endpoints included asymptomatic HT and recurrent cerebral infarcts.

Findings: A total of 305 patients, mean age 66±13.21 years, were randomised to dabigatran or aspirin a mean of 40.10±19.44 hours after symptom onset. The qualifying event was a TIA in 21%, and ischaemic stroke in79% of patients. Median NIHSS (IQR) was 1 (0-2), and mean infarct volume 3.2±6.5 ml. No symptomatic HT occurred. Asymptomatic petechial HT developed in 11/142 (7.8%) of dabigatran-assigned patients and 5/142 (3.5%) of aspirin-assigned patients (RR=2.32, 95% CI 0.78, 6.85). Baseline infarct volume predicted incident HT (OR 1.07; 95% CI 1.03-1.12, p=0.0026). Incident covert infarcts on day 30 imaging occurred in 9/142 (6.3%) of dabigatran and 14/142 (9.8%) of aspirin patients (RR=0.62, 95% CI 0.26, 1.48). There were no major bleeding events with either treatment.

Interpretation: Dabigatran given to patients with acute minor non-cardioembolic ischaemic stroke/TIA was safe and was associated with a risk of HT similar to aspirin.

Trial Registration Number: clinicatrials.gov NCT02295826

Funding Statement: DATAS II was funded by the Canadian Institutes for Health Research (G327075).

Declaration of Interests: Dr. Butcher has served as an advisory board consultant and received speaker’s fees and investigatorinitiated grant support from Boehringer-Ingelheim, Bayer, BMS-Pfizer and Servier. Dr. Sharma has served as an advisory board consultant and or received speaker’s fees and investigator-initiated grant support from Boehringer-Ingelheim, Bayer, BMS-Pfizer, Daiichi Sankyo and Servier. Dr. Benavente has served as an advisory board consultant and or received speaker’s fees from Boehringer-Ingelheim, Bayer, BMS-Pfizer and Servier. Dr. Field has served as an advisory board consultant and received speaker’s fees from BoehringerIngelheim, Bayer, BMS-Pfizer and Servier and investigator-initiated grant support from BoehringerIngelheim and Bayer (study medication). Dr. Hill has served as a consultant for Boehringer-Ingelheim. He has received grants to the University of Calgary from Medtronic, Stryker, Boehringer-Ingelheim Canada, Bayer Canada. Dr. Gioia has received speaker honoraria from Bayer, and BMS Pfizer and has served as an advisory board consultant for Bayer, and Servier Inc. Dr. Coutts has served as an advisory board consultant for BMS-Pfizer. Boehringer-Ingelheim is providing study drug for an investigator-initiated study led by Dr. Coutts.

Ethics Approval Statement: The trial was approved by research ethics review boards at each institution.

Keywords: Novel Oral Anticoagulant, Transient Ischemic Attack, MRI, Haemorrhagic Transformation

Suggested Citation

Butcher, Kenneth and Ng, Kelvin and Sheridan, Patrick and Field, Thalia S and Coutts, Shelagh B and Siddiqui, Muzzafar and Gioia, Laura C and Buck, Brian and Hill, Michael D and Miller, Jodi and Klahr, Ana and Sivakumar, Leka and Benavente, Oscar R and Hart, Robert G and Sharma, Mike, Dabigatran Treatment of Acute Non-Cardioembolic Ischaemic Stroke: A Randomised Controlled Trial (January 19, 2019). Available at SSRN: https://ssrn.com/abstract=3320200 or http://dx.doi.org/10.2139/ssrn.3320200

Kenneth Butcher (Contact Author)

University of Alberta - Division of Neurology ( email )

Edmonton, Alberta T6G 2R3
Canada

Kelvin Ng

McMaster University

1280 Main Street West
Hamilton, Ontario L8S 4M4
Canada

Patrick Sheridan

David Braley Cardiac, Vascular and Stroke Research Institute (DBCVSRI) - Population Health Research Institute

Canada

Thalia S Field

McMaster University

1280 Main Street West
Hamilton, Ontario L8S 4M4
Canada

Shelagh B Coutts

University of Calgary

University Drive
Calgary, Alberta T2N 1N4
Canada

Muzzafar Siddiqui

McMaster University

1280 Main Street West
Hamilton, Ontario L8S 4M4
Canada

Laura C Gioia

University of Montreal

C.P. 6128 succursale Centre-ville
Montreal, Quebec H3C 3J7
Canada

Brian Buck

University of Alberta

Edmonton, Alberta T6G 2R3
Canada

Michael D Hill

University of Calgary

University Drive
Calgary, Alberta T2N 1N4
Canada

Jodi Miller

McMaster University

1280 Main Street West
Hamilton, Ontario L8S 4M4
Canada

Ana Klahr

University of Alberta

Edmonton, Alberta T6G 2R3
Canada

Leka Sivakumar

University of Alberta

Edmonton, Alberta T6G 2R3
Canada

Oscar R Benavente

University of British Columbia (UBC)

2329 West Mall
Vancouver, British Columbia BC V6T 1Z4
Canada

Robert G Hart

McMaster University

1280 Main Street West
Hamilton, Ontario L8S 4M4
Canada

Mike Sharma

University of Alberta

Edmonton, Alberta T6G 2R3
Canada

Click here to go to TheLancet.com

Paper statistics

Downloads
86
Abstract Views
677
PlumX Metrics